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Abstract
Purpose Transdermal fentanyl is effective for the treatment of
moderate to severe cancer-related pain but is unsuitable for
fast titration. In this setting, continuous subcutaneous fentanyl
may be used. As data on the pharmacokinetics of continuous
subcutaneous fentanyl are lacking, we studied the pharmaco-
kinetics of subcutaneous and transdermal fentanyl. Further-
more, we evaluated rotations from the subcutaneous to the
transdermal route.
Methods Fifty-two patients treated with subcutaneous and/or
transdermal fentanyl for moderate to severe cancer-related
pain participated. A population pharmacokinetic model was
developed and evaluated using non-linear mixed-effects
modelling. For rotations from subcutaneous to transdermal
fentanyl, a 1:1 dose conversion ratio was used while the sub-
cutaneous infusion was continued for 12 h (with a 50 % ta-
pering after 6 h). A 6-h scheme with 50 % tapering after 3 h
was simulated using the final model.
Results A one-compartment model with first-order elimina-
tion and separate first-order absorption processes for each
route adequately described the data. The estimated apparent
clearance of fentanyl was 49.6 L/h; the absorption rate con-
stant for subcutaneous and transdermal fentanyl was 0.0358
and 0.0135 h−1, respectively. Moderate to large inter-
individual and inter-occasion variability was found. Around
rotation from subcutaneous to transdermal fentanyl, measured
and simulated plasma fentanyl concentrations rose and in-
creasing side effects were observed.
Conclusions We describe the pharmacokinetics of subcutane-
ous and transdermal fentanyl in one patient cohort and report
several findings that are relevant for clinical practice. Further
research is warranted to study the optimal scheme for rotations
from the subcutaneous to the transdermal route.
Keywords Fentanyl . Pharmacokinetics . Subcutaneous .
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Introduction
For the treatment of moderate to severe cancer-related pain,
strong opioids are the treatment of choice [1, 2]. Fentanyl is a
synthetic opioid with a high affinity for the μ-opioid receptor
and is 75–100 times more potent than morphine [3, 4]. Ac-
cording to international guidelines, fentanyl is not the opioid
of first choice [2], but nonetheless, it is widely used for the
treatment of cancer-related pain. Fentanyl is recommended in
patients with renal failure [2]. Furthermore, because the
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incidence of constipation is lower in fentanyl compared to
morphine [5–7] and it can be administered through a patch,
it is a popular drug for the treatment of cancer-related pain.
Fentanyl can also be used if an opioid rotation is necessary
after failure on another type of opioid. Its low molecular
weight and high lipid solubility make it suitable for transder-
mal delivery [8]. Although the first patches used a reservoir
design carrying risks of drug leakage or abuse, currently avail-
able patches have a matrix design. They release fentanyl at a
proposed rate of 12.5–100 μg/h and the amount delivered is
proportional to the surface area of the patch. As a gradient is
needed between the patch and the skin, the patch contains
more fentanyl than is released. A mean bioavailability of
92 % (57–146 %) has been reported [9]. Reservoir and matrix
patches and different types of matrix patches have been shown
to have similar pharmacokinetic profiles [10, 11]. The slow
decrease in fentanyl concentrations after transdermal patch
removal and the delay before achieving the maximum plasma
concentrations (both reflecting slow release of fentanyl) make
transdermal fentanyl (patches) unsuitable for fast titration in
patients with severe pain. In this setting, parenteral titration is
therefore preferred. Subcutaneous administration has been
proven to be safe and effective [12, 13] and has advantages
over the intravenous route as no vascular access is needed,
making it easier to change sites and avoiding complications
associated with indwelling intravenous catheters. In addition,
subcutaneous administration can also be applied safely in an
out-of-hospital setting [14].
In our cancer institute, patients with severe pain are prefer-
ably titrated with continuous subcutaneous opioids, and in this
setting, fentanyl is frequently used. However, little is known
about the pharmacokinetics of subcutaneously (sc) adminis-
tered fentanyl as opposed to the transdermal (td) route. As part
of a larger prospective pharmacologic opioid project, we stud-
ied the pharmacokinetics of fentanyl in hospitalized cancer
patients with moderate to severe cancer-related pain. The pur-
pose was to study the pharmacokinetics of fentanyl adminis-
tered via the subcutaneous and transdermal routes to cancer
patients. A second aim was to evaluate rotations from the
subcutaneous to the transdermal route.
Patients, materials and methods
Between January 2010 and November 2013, patients admitted
to the Erasmus MC Cancer Insti tute (Rotterdam,
The Netherlands) and treated with fentanyl for moderate to
severe cancer-related nociceptive pain were asked to participate
in the study. Fentanyl Sandoz® Matrix patches were used in
available doses of 12/25/50/75/100 μg/h and patches could be
combined. Patches were applied to the chest wall or upper arm
and were replaced every 72 h. The starting dose in opioid-naive
patients was 12 μg/h and doses in other patients were based on
previous treatment. In case of severe pain, patients were titrated
by continuous sc infusion with the possibility of an extra bolus
every hour. The dose of the bolus usually parallels the dose
given per hour. Doses were titrated based on clinical effects.
When pain control was reached and doses were stabilized, pa-
tients could be rotated to fentanyl (td) patches depending on the
clinical setting. For the rotation of sc to td fentanyl, a 1:1 dose
conversion ratio was used, based on data from previous studies
[15, 16]. After applying the patch, the sc administration was
continued in the same dose for 6 h, after which 50% of the dose
was given during an extra 6 h [17]. After 12 h of patch appli-
cation, the sc administration was stopped. Patients treated with
a patch were prescribed medication for the treatment of break-
through pain, mostly oral morphine or oxycodone in an imme-
diate release formulation but not rapid onset opioids. For all
patients, co-medication was screened for the concurrent use
of strong CYP3A4 inhibitors or inducers. Also, liver function
was checked based on the laboratory values of bilirubin, alanine
aminotranferase (ALT), aspartate aminotransferase (AST) and
albumin. The study was approved by the medical ethics review
board (MEC 09.332) and conducted in accordance with the
Declaration of Helsinki. Written informed consent was obtain-
ed from all participants. The trial was registered in the Dutch
Trial Register (Trial registration ID: NTR4369, http://www.
trialregister.nl/trialreg/admin/rctsearch.asp?Term=4369).
Pharmacokinetic sample collection
Patients were included in the study as soon as possible after
admission to the ward or after the start of fentanyl. Blood
samples for pharmacokinetic analysis were taken during a
maximum of 72 h after the start of fentanyl and after each
change in the opioid regimen (dose, route of administration).
The protocol prescribed sampling twice a day, around 8 am
and 8 pm, a baseline plasma sample before every change in the
regimen and a series of samples maximally once a day around
the administration of an extra subcutaneous bolus at baseline,
5, 15, 30 and 60 min after administration. Samples were col-
lected using potassium EDTA tubes. After centrifugation of
the tube, the supernatant was collected and stored at −70 °C
until analysis at the laboratory of Translational Pharmacology
(Erasmus MC Cancer Institute).
Measurements of fentanyl plasma concentrations
Fentanyl in plasma was quantitated using a validated UPLC-
MS/MSmethod consisting of aWaters Acquity UPLC sample
manager coupled to a triple quadruple mass spectrometer op-
erating in the multiple reaction monitoring mode (MRM) with
positive ion electrospray ionization (Waters, Etten-Leur,
The Netherlands). The multiple reaction monitoring transi-
tions was set at 337→188 for fentanyl and 342→188 for
the internal standard fentanyl-d5.
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Chromatographic separations were achieved on an Acquity
UPLC®BEHC18 1.7 μm 2.1×100mm column thermostated
at T=50 °C. A gradient at a flow rate of 0.350 mL/min was
achieved with mobile phase A, composed of 2 mM ammoni-
um formate and 0.1 % formic acid, and mobile phase B, com-
posed of methanol with 0.1 % formic acid. A linear gradient
was used, with 90%mobile phase A from 0–0.50 min follow-
ed by 90–0 %mobile phase A, from 0.50 to 2 min, holding on
0 % mobile phase A (i.e. 100 % mobile phase B) for 2 min.
This was succeeded by a linear gradient back to 90 % mobile
phase A from 4.0 to 4.1 min, which was held for 1.9 min to re-
equilibrate. The overall cycle time of the method was 6 min.
The calibration curves were linear over the range of 0.100 to
10.0 ng/mL with the lower limit of quantitation validated at
0.100 ng/mL for fentanyl. The extraction of 200 μL of plasma
involved a deproteinization step with 100 μL of internal stan-
dard solution in acetonitrile and 100 μL of acetone followed
by a simple liquid–liquid extraction with 1-mL ethyl acetate
after the addition of 100 μL of 4 % ammonium hydroxide. For
fentanyl (linear calibration range 0.100–10.0 ng/mL), the
within- and between-run precisions at five tested concentra-
tions, including the lower limit of quantitation (LLQ), were
≤5.52 and ≤6.12 %, respectively, while the average accuracy
ranged from 88.5 to 94.0 %. No adsorption of fentanyl was
observed to the sampling and/or storing tubes. The inter-day
coefficient of variation (CV) at five tested concentrations, in-
cluding the LLQ, was ≤7.5 % in individual validation runs.
Population pharmacokinetic model for fentanyl
The analysis of log-transformed concentration–time data was
carried out with non-linear mixed-effects modelling in
NONMEM (version 7.3; Icon Development Solutions, Hano-
ver, MD) by means of the first-order conditional estimation
method with or without eta-epsilon interaction [18]. Model
building was assisted by Perl-speaks-NONMEM (PsN ver-
sion 4.2.0, http://psn.sourceforge.net/) [19, 20] and the
graphical evaluation with R (version 3.0.3, http://www.r-
project.org/) and Xpose (version 4.4.1, http://xpose.
sourceforge.net/) [21].
As a starting point, a one-compartment model with first-
order absorption preceded by a lag time was used. Several
model components were evaluated, including one- versus
two-compartment disposition models, alternative absorption
models following transdermal administration (first- versus ze-
ro-order), differences between the two administration routes in
absorption parameters, i.e. absorption rate constant (ka) and
lag time (tlag), and inclusion of allometrically scaled body
weight on disposition parameters. Concentrations below the
lower limit of quantification comprised less than 1 % of the
data and were discarded from the analysis.
Inter-individual variability (IIV) in pharmacokinetic pa-
rameters was modelled using log-normal models. An occasion
was defined as a transdermal dose followed by at least one
observation, and inter-occasion variability (IOV) was evaluat-
ed on absorption parameters as proposed by Karlsson and
Sheiner [22]:
Pik ¼ P  eηiþ Kik
where Pik represents the parameter P for the ith individual on
occasion k, P is the typical parameter for the studied popula-
tion, ηi is the patient-specific random effect describing the
discrepancy between the typical and individual parameter
and κik is the random effect accounting for the IOV. ηi and
κik are assumed to be normally distributed with mean zero and
estimated variance ω2 and π2, respectively.
Alternative residual error models were evaluated, including
homoscedastic or heteroscedastic residual errors as well as a
model combining both types of error.
Model evaluation
The selection between alternative models during the model-
ling process was based on scientific plausibility and statistical
significance. Statistical evaluation comprised the analysis of
goodness-of-fit plots, precision of parameter estimates, condi-
tion number and the likelihood ratio test based on the change
of the objective function value (OFV). The OFV is given by
minus twice the log likelihood, and a difference in OFV
(ΔOFV) between nested models is approximately χ2 distrib-
uted. AΔOFVof 3.84, 6.64 and 10.8 corresponds to p values
of 0.05, 0.01 and 0.001, respectively, when one parameter is
added to the model (1 df). The Akaike information criterion
(AIC) was used to compare non-hierarchical models. The
magnitude of η- and ε- shrinkage was computed according
to Karlsson and Savic [23] to judge the reliability of various
diagnostic plots. The uncertainty of parameter estimates was
assessed using the non-parametric bootstrap procedure in PsN
(1000 bootstrap datasets). The predictive performance of the
final model was evaluated with a population prediction-
corrected visual predictive check (pcVPC) through 1000 sim-
ulations of the dataset [24].
Results
Patients
Plasma samples for pharmacokinetic analysis were avail-
able for 52 patients (Table 1). Three patients participated
in the study twice. Treatment with td and sc fentanyl in
relation to the observations for all patients is shown in
supplemental figure 1. In 13 patients, samples were avail-
able during sc treatment without previous td administra-
tion; in 9 patients, samples were available during
Eur J Clin Pharmacol (2016) 72:459–467 461
treatment with td fentanyl without previous or concurrent
sc treatment; and in 32 patients, samples were available
during treatment with sc or td fentanyl, but the other
treatment route was given until shortly before sampling
(semi-simultaneous treatment) or simultaneously. The ma-
jority of patients (n= 33) already used transdermal fenta-
nyl before admission. In total, 942 fentanyl plasma sam-
ples were available with a median of 15 sparse samples
per patient (range 1–86) and a median concentration of
1.33 ng/mL (range 0.122–10.7 ng/mL). One patient used
a strong CYP3A4 inducer—carbamazepine 200 mg—dur-
ing his study period. In none of the patients, the combi-
nation of AST and/or ALT above upper limit of normal
(ULN), bilirubin above ULN and albumin below lower
limit of normal was found, and therefore it was concluded
that none of the patients had liver failure. Doses for the
transdermal route varied from 12 to 400 μg/h (median
50 μg/h), and doses for the continuous subcutaneous in-
fusion ranged from 10 to 300 μg/h (median 75 μg/h).
Fentanyl pharmacokinetics
The pharmacokinetics of fentanyl-administered sc and td were
best described by a one-compartment model with first-order
elimination and separate first-order absorption processes for
each route. The residual error was most adequately described
by a heteroscedastic model parameterised as an additive mod-
el on the log-scale. Due to the sparse sampling design, we
were unable to estimate all model parameters satisfactorily,
particularly with respect to parameters describing the absorp-
tion part. Hence, the apparent volume of distribution (V/F)
was fixed to 280 L [25]. A sensitivity analysis carried out with
values of V/F ±50 % fixed in 10 % increments showed the
model to be insensitive to the value and other parameter esti-
mates to be stable within the tested range, with only tlag and ka,
sc varying slightly (less than ±25 % deviation from the final
PK parameter values). Inclusion of allometrically scaled body
weight on CL/F and V/F was found to explain some variabil-
ity and was kept to increase model stability. The final popula-
tion model parameters including bootstrap results are present-
ed in Table 2.
The estimated population value for CL/F in a 70-kg subject
was 49.6 L/h. The estimation of a tlag for td administration led
to an improvement of the model fit (p value <0.001) with the
final value of 4.73 h. In contrast, the inclusion of a tlag was not
relevant for sc administration. The model was compared with
a model with zero-order absorption for td fentanyl, and the
AIC was clearly in favour of the first-order absorption (AIC
more than 60 points lower). The estimated absorption rate
constant for subcutaneous fentanyl was 0.0358 h−1 and for
transdermal fentanyl 0.0135 h−1.
IIV was included on ka for both routes (93.5 and 42.4 % for
sc and td, respectively), td bioavailability and apparent clear-
ance (CL/F). Bioavailability of td fentanyl was allowed to dif-
fer between individuals with an estimated variability of 42.3%.
IOVon td ka resulted in a significant improvement of the model
(p<0.01) with an estimated value of 32.8 %. The consequence
for rate and extent of absorption following td administration,
given these characteristics, is illustrated in Fig. 1.
The model was found to describe the observed concentra-
tions well (Fig. 2). The performance of the model to predict
median concentrations was good as illustrated by a pcVPC
shown in Fig. 3. Additional goodness-of-fit plots can be found
in Supplemental data.
Evaluation of rotations from subcutaneous to transdermal
fentanyl
For 14 patients, multiple plasma samples were available
shortly before and after rotation from sc to td fentanyl
using the 12 h scheme. In 12 of these patients, a rise in
plasma fentanyl concentrations was seen after application
of the first patch. Furthermore, the intensity of side effects
Table 1 Patient characteristics
Characteristics (n= 52) No. (%)
Median age (years)—range 63 (23–80)
Sex
Male 33 (63)
Female 19 (37)
Race
Caucasian 47 (90)
Other 1 (2)
Unknown 4 (8)
WHO performance status
0 0
1 19 (37)
2 17 (33)
3 4 (8)
Unknown 12 (23)
Median body mass index—range 25 (18–40)
Median NRS in rest at start of fentanyl or on
admission—range
5 (2–10)
Primary tumour localization
Breast 8 (15)
Colorectal 5 (10)
Prostate 7 (13)
Soft tissue sarcoma/GIST 6 (12)
Urinary tract (including the kidney) 8 (15)
Other 18 (35)
Median albumin—range 39 (29–49)
Median AST (U/l)—range 31 (13–216)
Median ALT (U/l)—range 22 (7–131)
Median total bilirubin (μmol/L)—range 7 (3–16)
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increased in 9 patients while in 3 patients, severe
fentanyl-related toxicity occurred, necessitating adjust-
ment of treatment. The severe toxicity consisted of respi-
ratory depression, severe drowsiness and nausea.
By using the final model, fentanyl plasma concentrations
expected around and after rotation were predicted for a popu-
lation of 52 patients through stochastic simulation. Figure 4
illustrates plasma fentanyl concentrations during the rotation
from a sc infusion of 50 μg/h to a td patch with a delivery rate
of 50 μg/h using the 12-h scheme. After the application of the
td patch, the simulated median peak concentration is higher
than the steady-state concentration of subcutaneous fentanyl.
In addition, concentrations immediately after the end of the
rotation scheme, i.e. 12 h after the application of the patch, are
very variable with the 10th and 90th percentiles equal to 0.87
and 3.22 ng/mL (median value 1.68 ng/mL). Simulated fen-
tanyl plasma concentrations using a 6-h scheme [26] produced
similar results, and comparative plots can be found in Supple-
mental data.
Discussion
This prospective study in Caucasian cancer patients treated
with fentanyl provides us with new insights into the pharma-
cokinetics of fentanyl which are relevant for clinical practice.
Table 2 Typical population
pharmacokinetic parameter
estimates for subcutaneous and
transdermal fentanyl and
bootstrap analysis results
Parameter (units) NONMEM estimate (%RSE)a Bootstrap mean (95 % CI)b
Structural model parameters
ka subcutaneous (h
−1) 0.0358 (24.4) 0.0374 (0.0248, 0.0555)
tlag transdermal (h) 4.73 (21.2) 4.65 (2.25, 6.98)
ka transdermal (h
−1) 0.0135 (16.8) 0.0140 (0.0105, 0.0188)
V70kg/F (L)
c 280 (fix) –
CL70kg/F (L h
−1)d 49.6 (9.36) 50.4 (40.9, 61.6)
Inter-individual variability (%CV)
ka subcutaneous 93.5 (15.2
e) 91.1 (59.6, 119)
F transdermal 42.3 (30.0e) 45.7 (19.7, 67.8)
ka transdermal 42.4 (23.9
e) 41.4 (10.5, 59.2)
CL/F 43.2 (15.2e) 41.6 (27.1, 53.9)
Inter-occasion variability (%CV)
ka transdermal 32.8 (51.1
e) 39.2 (12.0, 77.0)
Residual unexplained variability (%CV)
Proportional residual error 23.4 (5.17f) 23.2 (20.6, 25.6)
a The condition number of the final model was 24.99
bMean and 95 % bootstrap percentile confidence intervals. Runs with estimates near a boundary (n= 150),
rounding errors (n= 165) or crashed (n= 3) were skipped when calculating results
cV70kg/F= 280 × (WT/70)
d CL70kg/F= estimate × (WT/70)
0.75
e%RSE is reported on the approximate standard deviation scale (standard error/variance estimate)/2. η-shrinkage
for inter-subject variability ranged between 14.6 and 48.4 % and η-shrinkage for inter-occasion variability was
>35 %
f ε-shrinkage was 5.97 %
CI confidence interval; CL70kg/F apparent clearance for a subject with 70 kg; %CV percent coefficient of varia-
tion, reported as sqrt(variance) × 100 %; F bioavailability; ka absorption rate constant; %RSE relative standard
error; tlag absorption lag time; V70kg/F apparent volume of distribution for a subject with 70 kg; WTweight (kg)
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Fig. 1 Stochastic simulation of fentanyl plasma concentrations versus
time after application of a transdermal patch with a delivery rate of
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Firstly, we developed a population pharmacokinetic model
for sc and td fentanyl from a high number of sparse samples in
this patient cohort. We found that a one-compartment model
adequately describes the pharmacokinetics of sc and td
fentanyl, similarly to the results of previous studies with td
fentanyl [27, 28]. We were able to distinguish inter-individual
variability between absorption and elimination pharmacoki-
netic parameters that along with inter-occasion and residual
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Fig. 2 Goodness-of-fit plots for
the final model. Observed
fentanyl plasma concentrations
versus population predictions (left
panels) and individual predictions
(right panels) in normal (top
panels) and logarithmic scale
(bottom panels). The solid line
represents the line of identity
(x= y) and the dashed line
represents a linear regression line
Fig. 3 Population prediction-
corrected visual predictive check
for the final model for
subcutaneous and transdermal
fentanyl. The x-axis represents the
time after the first recorded dose
of fentanyl after admission. Dots
are the population predicted-
corrected individual observations,
and the solid and dashed lines
represent the median and the 10th
and 90th percentiles of the
observed data, respectively. The
shaded areas represent the
simulation-based 95 %
confidence interval for the
simulated data percentiles
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variability explain the high variability in plasma concentra-
tions and possibly also clinical effects.
Similar PK models have been described following td ad-
ministration previously [27, 28]. In our study, the CL/F was
estimated to 49.6 L/h, which is similar to the values of 40.8
and 42.4 L/h obtained in previous PK studies [10, 29]. Fur-
thermore, in line with previous models, the absorption from td
patches over 72 h was found to be closer to a first-order than to
a zero-order process, with a potential to lead to fluctuations in
plasma concentrations during treatment. Indeed, fluctuation in
plasma concentrations has been reported in several studies
[30–33]; however, the clinical relevance of this finding was
never widely acknowledged. In clinical practice, however,
many patients report either lower pain scores and/or more side
effects after patch change, and on the other hand, for worsen-
ing of pain during the third day, a patch is used [16, 34].
The estimated absorption rate constant and absorption lag
time are in agreement with the values found by Bista et al. [28]
(0.013 h−1, ka) and Kokubun et al. [27] (0.0145 h
−1 and 4.93,
ka and lag time) for td fentanyl. Such slow absorption relative
to elimination (absorption and elimination half-lives 51.3 and
3.91 h, respectively) results in that the decline in plasma con-
centrations after achieving the peak following transdermal ad-
ministration reflects absorption rather than elimination. The
Tmax predicted by our model in a typical patient was about
20.5 h after the administration of a patch. This value is known
to vary substantially between patients and values in the range
12–48 h have been reported [35]. The td absorption with large
variability is illustrated in Fig. 1.
For sc fentanyl, published PK data are limited. In the only
other study in patients treated with continuous infusion of sc
fentanyl, only one plasma sample was taken showing consid-
erable variability, but no PK parameters were presented [36].
Capper et al. [37] described the pharmacokinetics of fentanyl
after a bolus of 200 μg fentanyl sc in nine healthy volunteers
and reported a CL/F of 53.7 L/h, similar to our estimate, and a
rapid absorption (Tmax 10–30 min). We found a slow absorp-
tion with substantial IIV in a situation in which fentanyl dos-
ages were titrated using continuous infusion with extra bolus-
es as needed for pain control. The estimation of a separate ka
following sc boluses was tested but not supported by the data.
In addition, the model was evaluated with a fast absorption
process following sc administration by fixing ka for this route
(2 h−1). However, goodness-of-fit plots and the fit of the mod-
el was statistically significantly worse (p<0.001). In four pa-
tients in our study, plasma samples were available after stop-
ping sc fentanyl because of rotation to another type of opioid.
In all, a slow decrease in fentanyl plasma concentrations was
noticeable which supports our data. It may be that also after
subcutaneous treatment, some subcutaneous dose depot is
formed, as has been reported for td fentanyl [9], but there
are no firm data following sc infusion. Thus, our model de-
scribes sc infusion data, but mechanistic conclusions should
not be drawn. However, if the slow absorption would be that
slow, it suggests that continuous fentanyl is less suitable for
fast titration.
High to moderate variability in PK parameters and plasma
concentrations has been reported before for td fentanyl, but
literature on sc fentanyl is scarce. Kokubun et al. and Bista
et al. [28] estimated moderate IIVon CL/F to 43.5 and 38.5%,
respectively, following td patches. Although there are differ-
ences in patch type (reservoir versus matrix) and study
Fig. 4 Simulated fentanyl plasma concentrations during the rotation
from a subcutaneous infusion of 50 μg/h at steady state to a
transdermal patch with a delivery rate of 50 μg/h using the 12-h
scheme (1000 simulations of 52 subjects). Following this scheme, the
subcutaneous administration is continued in the same dose for 6 h after
applying the transdermal patch, after which 50 % of the dose is given
during an extra 6 h. The simulated solid line represents the median of the
simulated data, and the shaded area represents the 80 % prediction
interval. The vertical dashed line represents the time of patch application
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populations, i.e. regarding the amount of sc fat/body mass
index and hepatic metabolism, IIV was in agreement with
our estimate of 43.2 %. The IIVon ka in the study of Kokubun
was substantially greater (71.9 %) than the 42.4 % we obtain-
ed, but we also found different occasions as a significant
source of variability (IOV, 32.8 %). Other studies have report-
ed substantial variation in bioavailability (range 60 to 97 %),
in the measured rate of absorption (e.g. 12.5 to 60.4 μg/h with
a patch of 50 μg/h) [29] and in inter- and intra-subject vari-
ability in plasma fentanyl concentrations (50.7 and 34.4 %,
respectively) [30].
Lastly, this is to our knowledge the first evaluation of rota-
tions from sc to td fentanyl, using the scheme described by
Kornick et al. [17] who studied rotations from the intravenous
(iv) to the transdermal route. More recently, a scheme using a
two-step taper of iv fentanyl in 6 h was found to be safer than
the 12-h method [26]. In a PK study by the same group, using
the 6-h scheme, a rise in plasma concentrations was seen after
3 h but without adverse effects [38]. According to the current
study, the use of the 12-h scheme and a 1:1 dose conversion
may lead to a rather steep rise in plasma concentrations for
some patients and clinically evident toxicity. Based on the
final model, we simulated rotations using the 6-h scheme. This
scheme may also lead to a rise in plasma levels and therefore
potential toxicity. This is probably caused by the fact that
plasma concentrations fall slower after stopping a sc adminis-
tration than after an iv administration and by the finding that
absorption following td administration appears to follow a
first-order process. For confirmation of our findings, we have
planned a prospective pharmacokinetic evaluation study of
different rotation schemes without overlap of routes and with
or without dose reduction of the first patch.
Strengths of our study are the longitudinal data that we
assembled in one patient cohort and the large number of sam-
ples available for PK analysis. One limitation in our study was
that, although we were able to estimate IIV and IOV variabil-
ity in PK parameters, due to a limited sample size, we did not
investigate possible sources of variability through covariate
modelling. Furthermore, due to semi-simultaneous adminis-
tration following different routes of administration, the ob-
served concentrations were the sum of those obtained follow-
ing each route. Especially, many patients started on sc fentanyl
after hospital admission while they already used fentanyl td at
home, and sc bolus injections for rescue were frequently ad-
ministered over the full study period. Although the semi-
simultaneous administration was accounted for in modelling,
the study design was not optimal for modelling purposes.
In conclusion, this study describes the pharmacokinetics of
sc and td fentanyl in one patient cohort. Findings relevant for
clinical practice are the moderate to large IIVand IOVand that
absorption following td administration potentially may lead to
fluctuations in plasma concentrations. Furthermore, published
rotation schemes for rotations from intravenous to transdermal
fentanyl might not be applicable on rotations from subcutane-
ous to transdermal fentanyl.
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